Researchers in Australia have identified the first blood biomarker – a chemical identifier in the blood – for multiple sclerosis (MS).
The findings are the result of a 12 year study that will allow scientists to determine which type of MS a patient has with 85-90 per cent accuracy. Diagnosing patients with MS has been a notoriously lengthy process, but these new results show that a blood test could greatly simplify and speed up the process.
The international study was led by Macquarie University researchers Dr Edwin Lim and Professor Gilles Guillemin. Commenting on the findings, Prof Guillemin said: “This is a significant discovery because it will facilitate the ability to quickly and simply make a prognosis of the three types of MS and will allow clinicians to adapt their treatment for MS patients more accurately and rapidly.”
“With the support of Dianti MS Pty, an Australian company, we are currently developing a new prognostic kit with Dr Alban Bessede at ImmuSmol, France which will help the medical profession and laboratories around the world quickly and easily identify the type of MS the patients has,” he added.
The researchers say that a clinical blood test kit could potentially be available in as little as two years, and the research will also likely provide an entirely new avenue of multiple sclerosis therapeutics with the possibility for the development of a more personalised treatment regime for those affected.
“The unique information that we will receive from the biomarker within an individual, means that it could also be possible to develop biomarker guided personalised treatment for each patient,” said Dr Lim, the lead researcher of the study, who is currently based at Macquarie University and who was previously an MS Research Australia Postdoctoral Research Fellow at UNSW Sydney, where the research for this study was first initiated.
Dr Matthew Miles CEO of MS Research Australia one of the early and ongoing supporters of this work, commented: "MS Research Australia has been an enthusiastic supporter of this research right from its inception. We have been excited to be part of the translation of this initially fundamental research into a potential clinical test. This has the clear capacity to be the first ever blood biomarker for the prognosis of MS, and in doing so will meet one of the real unmet needs in the clinical management of MS."
The results are also likely to be integral in understanding the progression of other diseases caused by inflammation and neurodegeneration, including Alzheimer's, Parkinson's and Amyotrophic Lateral Sclerosis, also known as Lou Gehrig's or motor neurone disease.
"The test itself relies on detecting compounds within a specific biochemical pathway that uses a chemical called tryptophan. Tryptophan is known to be involved in brain inflammation, and so by increasing our understanding of how our cells process tryptophan, we will be better able to identify its involvement in many types of neurodegenerative diseases," Professor Guillemin concluded.
Source: MS-UK (06/02/17)